What Nurotron Biotechnology does

Nurotron Biotechnology (浙江诺尔康神经电子科技股份有限公司) is a Hangzhou-headquartered neuroelectronic medical device company founded in 2006 that develops, manufactures, and sells implantable neural stimulation systems across four therapeutic lines: hearing reconstruction (cochlear implants CS-20A/CS-30A, auditory brainstem implant WH-01A), visual reconstruction (artificial retinal prosthesis for RP and AMD patients), urinary system neuromodulation (SacralStim implantable sacral nerve stimulator, TTNS-W1 transcutaneous tibial nerve stimulator, IVES intravesical electrical stimulator), and brain neurological disease treatment (deep brain stimulation for Parkinson's, dystonia, essential tremor). The company is China's first enterprise to hold complete independent intellectual property rights for cochlear implant technology and ranks as the world's fourth country after the US, Australia, and Austria to produce cochlear implants domestically. Technical differentiators include 24+2 electrode channels (highest globally), 3.0T MRI-compatible implant design (CS-30A), Mandarin-specific C-Tone four-tone coding strategy, and the only Bluetooth direct-connect system compatible with iOS, Android, and HarmonyOS.

Nurotron operates a direct-to-patient, manufacturer-direct sales model supplemented by regional sales offices in Beijing, Zhengzhou, Hefei, Chengdu, and Guangzhou, plus channel partnerships in 20+ countries including Spain, Pakistan, Russia, India, and Brazil. Revenue is generated primarily through one-time hardware sales of cochlear implants (ASP approximately RMB 78,000 pre-VBP, RMB 50,000 post-2025 national procurement) and speech processors, complemented by after-sales service, parts replacement, and government-assisted charity programs. End customers span 20,000+ hearing-implant users across age groups 1-80, including direct-pay patients, national medical insurance beneficiaries (~70-80% reimbursement in Zhejiang province), and charity program recipients through partnerships with China Disabled Persons' Welfare Foundation and Zhejiang Provincial Disabled Persons' Federation.

The company is designated a national-level Specialized 'Little Giant' (专精特新) enterprise, holds 241 domestic and international patents (46 invention patents), and has won the National Science and Technology Progress Award twice (2015 and 2023). R&D is led by CTO Zhou Daomin (AIMBE Fellow, former Chief Scientist at Second Sight Medical Products) with a US R&D center in California and a wholly-owned engineering operation in Hangzhou Future Sci-Tech City. In May 2025, Hangzhou municipal and district state-owned capital completed a strategic equity investment of several hundred million RMB to accelerate global expansion and neuroelectronics business development.

Name

Nurotron Biotechnology

Legal name

浙江诺尔康神经电子科技股份有限公司

Website

https://nurotron.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

101–250 employees

Short description

Nurotron Biotechnology is a Hangzhou-based neuroelectronic medical device company developing implantable neural stimulation systems — including cochlear implants, auditory brainstem implants, artificial retinas, sacral nerve stimulators, and deep brain stimulators — serving hearing-impaired, visually-impaired, and neurological disease patients across 20+ countries.

Ownership category

akta.pro rank

Product category

Neuroelectronic Implantable Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

• Cochlear implant devices
• Auditory brainstem implants
• Neuroelectronic medical devices
• Artificial retinal prosthesis
• Sacral nerve stimulation

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. 神经电子医疗器械销售: 公司主要收入来源于人工耳蜗植入体、言语处理器及其他神经调控/神经假体产品（骶神经刺激器、膀胱腔内电刺激系统、脑深部电刺激系统、人工视网膜等）的生产与销售，采用一次性设备销售模式
2. 售后服务与配件供应: 通过365售后服务体系提供设备维护、维修保养、配件更换等服务，确保客户长期使用
3. 政府采购与医保渠道: 产品纳入国家医保和集中采购目录，通过政府医疗救助项目（启明行动等）实现批量销售

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels7 records

Core offering

Nurotron Biotechnology designs, manufactures, and sells a full portfolio of implantable neuroelectronic medical devices spanning four therapeutic lines: hearing reconstruction (cochlear implants and auditory brainstem implant systems), vision reconstruction (artificial retinal prosthesis), urinary system neuromodulation (implantable sacral nerve stimulators, transcutaneous tibial nerve stimulators, intravesical electrical stimulators), and deep brain stimulation for movement disorders. Core revenue comes from one-time sales of implantable hardware (implants + speech processors) bundled with after-sales service.

Product overview

Nurotron Biotechnology (浙江诺尔康神经电子科技股份有限公司) is a neuroelectronic medical device company headquartered in Hangzhou, China, offering four core therapeutic product lines: hearing reconstruction (人工耳蜗系统和听觉脑干植入系统), visual reconstruction (人工视网膜系统), urinary system neuromodulation (骶神经刺激系统、穿戴式经皮胫神经刺激器、膀胱腔内电刺激系统), and brain neurological disease treatment (脑深部电刺激系统). The hearing reconstruction line includes two generations of cochlear implants (CS-30A, CS-20A) paired with two speech processor models (远航/Voyager, 清听/Airum). The company operates on a direct-to-patient model with a 365-day after-sales service system. Products are manufactured in Hangzhou with an R&D center in California, USA.

Differentiator

Problem solved

Functional benefit

Products and services

• CS-30A Cochlear Implant (Implant 3.0) Third-generation cochlear implant featuring 3.0T MRI compatibility without magnet removal, 0.3mm ultra-thin electrode tip, and 3.9mm slim implant body that reduces surgical bone grinding volume. Designed for patients with severe to profound sensorineural hearing loss.
• CS-20A Cochlear Implant (Implant 2.0) Second-generation cochlear implant with 24+2 electrode channels (24 intracochlear + 2 extracochlear electrodes), 20% smaller volume than predecessor, and three electrode length options for precise implantation. Indicated for severe to profound sensorineural hearing loss across all ages.
• Voyager (远航) Speech Processor 3.0 Third-generation speech processor with dual-core digital signal processing chip, intelligent scene recognition (silent/noise/conversation/music auto-switching), Tencent SkyMark noise reduction, C-Tone Mandarin tonal coding strategy, E Voice and ABeam microphone noise reduction, and Bluetooth connectivity for iOS/Android/HarmonyOS.
• Airum / NSP-100A (清听) All-in-One Speech Processor All-in-one behind-the-ear speech processor with 10.8mm thickness, discreet concealed wearing profile, intelligent noise reduction, and direct control via the Nurolink mobile app. Designed to reduce structural complexity and maintenance requirements.
• Auditory Brainstem Implant WH-01A (ABI) Auditory brainstem implant with 16 electrodes on a 5.5mm x 3.5mm intracochlear array, specialized high-rate stimulation chip, and three-layer safety mechanism. Indicated for patients who cannot benefit from cochlear implants due to cochlear nerve abnormalities or cochlear malformations. Standard product lifetime exceeds 80 years; can withstand 2.5J impact.
• Artificial Retinal Prosthesis System Implantable artificial retinal prosthesis designed to restore useful vision for individuals blinded by retinal diseases including retinitis pigmentosa (RP) and age-related macular degeneration (AMD), which cause photoreceptor cell degeneration.
• SacralStim (IS-10A) Implantable Sacral Nerve Stimulation System Implantable sacral nerve stimulation system that treats refractory overactive bladder (OAB) through electrical stimulation of the sacral nerves. Indicated for patients unresponsive to two or more drug or behavioral therapies.
• TTNS-W1 Wearable Transcutaneous Tibial Nerve Stimulator Non-implantable, wearable transcutaneous tibial nerve stimulator that provides convenient at-home treatment for overactive bladder, self-administered by patients without surgical implantation.
• IVES Intravesical Electrical Stimulation System Non-surgical, minimally invasive intravesical electrical stimulation system that delivers electrical pulses directly inside the bladder to improve bladder contraction and voiding efficiency for underactive bladder symptoms. Reversible therapy.
• Deep Brain Stimulation (DBS) System Deep brain stimulation system for treatment of movement disorders including Parkinson's disease, dystonia, and essential tremor. Precisely modulates neural activity in deep brain structures to significantly alleviate tremor, rigidity, and gait difficulties.

Quantifiable outcome

• 2万名+听障患者通过诺尔康人工耳蜗重获听力，覆盖全球20+国家
• +5 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature7 records

Partnerships

16 partnerships are on record, tiered major, core and minor.

• 杭州师范大学附属医院majorStrategic or Co-development Partner · 4 September 2024杭州师范大学附属医院周雪华主任与李圆主任领衔的医疗团队完成诺尔康CS-30A植入体首例临床手术，标志着CS-30A从研发到临床应用的重大跨越
• Prof. Thomas Lenarz（德国汉诺威医学院）majorStrategic or Co-development Partner · 30 April 2024诺尔康与国际耳科泰斗Prof. Thomas Lenarz开展深度合作，Prof. Lenarz是全欧洲最大人工耳蜗植入中心（年均手术超600台）的耳鼻喉科教授，双方将在人工耳蜗和听觉脑干植入临床研究、新产品共同研发等领域开展合作
• 中国人民解放军总医院（国家耳鼻咽喉疾病临床医学研究中心）coreStrategic or Co-development Partner · 7 April 2023诺尔康作为十四五国家重点研发计划"人工耳蜗内耳重复药物递送电极技术研究及样机研制"项目主要承担单位，与解放军总医院、北大人民医院、同仁医院、北京协和医院、清华大学等十余家单位共同攻关，诺尔康负责国产人工耳蜗产业化
• 上海交通大学医学院附属第九人民医院（吴皓教授团队）coreStrategic or Co-development Partner · 26 January 2021诺尔康与上海九院听觉中心联合研发国产人工听觉脑干植入系统(ABI)，吴皓教授于2022年1月26日主刀完成首例国产听觉脑干植入手术，双方在产品研发、临床试验、技术转化等方面进行深度合作，共同推动国产听觉脑干植入技术发展
• 中华医学会耳鼻咽喉头颈外科学分会majorStrategic or Co-development Partner诺尔康参与2023年全国耳科年会等中华医学会主办的学术会议，展示产品技术并开展学术交流
• 浙江省残联/中国残疾人福利基金会majorStrategic or Co-development Partner诺尔康长期向中国残疾人福利基金会、浙江省残联等机构捐赠人工耳蜗，发起"牵手计划"、"聪慧行动"等慈善活动
• 巴基斯坦医疗机构minorChannel Partner/ Reseller/ Distributor诺尔康人工耳蜗在巴基斯坦正式登陆，通过当地医院和医生为巴基斯坦听障患者提供人工耳蜗植入手术和服务
• Biotech Innovation & Solutions, S.L.（欧盟代表公司）majorChannel Partner/ Reseller/ Distributor诺尔康欧盟代表公司总部位于西班牙巴塞罗那医疗产业聚集区，代表诺尔康参加2022西班牙耳鼻喉国民会议等学术活动，在西班牙及欧洲市场推广销售诺尔康人工耳蜗产品
• 浙江大学医学院附属儿童医院majorStrategic or Co-development Partner诺尔康与浙江大学医学院附属儿童医院共同完成《基于全景智能辅听技术的可穿戴式人工耳蜗系统》项目，获2022年度浙江省科学技术进步奖三等奖
• 郑州大学第一附属医院majorStrategic or Co-development Partner诺尔康与郑州大学第一附属医院等共同完成《听力障碍的精准诊断和全生命周期听力康复体系的构建和推广》项目，获2023年中国康复医学会科学技术奖一等奖
• 腾讯（天籁技术）majorTechnology or Integration诺尔康远航(Voyager)言语处理器搭载腾讯天籁技术，实现智能场景识别功能
• 清华大学majorStrategic or Co-development Partner诺尔康作为十四五国家重点研发计划项目参与单位，与清华大学等高校在神经电子领域开展合作研究
• 浙江大学医学院附属第四医院majorStrategic or Co-development Partner诺尔康与浙江大学医学院附属第四医院等共同完成的"儿童感音神经性聋精准防控新策略及临床应用推广"项目荣获2025年中华医学科技奖二等奖
• 中国-非洲总商会浙江代表处minorGTM or Marketing Partner诺尔康向中国-非洲总商会浙江代表处捐赠10套自主研发的人工耳蜗设备，用于帮助非洲听障人士
• 杭州电子科技大学信息工程学院majorStrategic or Co-development Partner诺尔康与杭州电子科技大学信息工程学院共同完成"一体式微型人工耳蜗智能辅听系统"项目，获2024年度浙江省科学技术进步三等奖
• 浙江工业大学majorStrategic or Co-development Partner诺尔康与浙江工业大学共同完成相关科研项目

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cochlear Limited: Australian global leader in cochlear implants (~50%+ world market share) and the company Nurotron most directly competes with. Both sell implantable hearing systems with electrode arrays, sound processors, and surgical workflow tooling to ENT surgeons and hearing clinics globally.
• MED-EL: Austrian manufacturer of cochlear implants and the global pioneer of auditory brainstem implants (ABI). Directly comparable product portfolio to Nurotron across both CI and ABI categories, serving similar patient populations and surgical centers.
• Advanced Bionics (Sonova): US cochlear implant business (acquired by Sonova in 2022) competing in the same hearing implant space as Nurotron's CS-30A/CS-20A. Targets similar severe-to-profound hearing loss population with comparable electrode array and sound processor technologies.
• Oticon Medical (Demant): Danish hearing implant manufacturer (Demant Group subsidiary) producing cochlear implants and bone-conduction hearing systems. Competes with Nurotron in both cochlear implant and hearing implant reconstruction markets globally.
• Second Sight Medical Products: US company developing retinal prosthetics (Argus II) — directly comparable to Nurotron's artificial retinal prosthesis product line for RP/AMD blindness. Nurotron's CTO Zhou Daomin was previously Chief Scientist here, indicating direct technology lineage.

Regional players

• Beijing Pins Medical: Chinese domestic leader in implantable neuromodulation (DBS for Parkinson's, SCS for chronic pain, sacral nerve stimulation). Comparable product portfolio to Nurotron's DBS and urinary neuromodulation lines, competing primarily in the Chinese market.
• Listent Medical: Chinese cochlear implant manufacturer (also Hangzhou-based) competing directly with Nurotron in domestic Chinese hearing implant market. Comparable product category, target patients, and hospital channel, primarily serving China.

Broad incumbents

• Boston Scientific Neuromodulation: Global medtech incumbent with significant DBS and spinal cord stimulation business. Comparable to Nurotron's DBS and neuromodulation products but as part of a much broader device portfolio (cardiovascular, endoscopy, etc.) rather than a focused neuroelectronics specialist.
• Abbott Neuromodulation: Global medical device company with DBS and neuromodulation portfolio (acquired St. Jude). Comparable to Nurotron's DBS product line but operates as a diversified incumbent across many therapeutic areas rather than a focused neuroelectronics player.
• LivaNova: Global neuromodulation company with vagus nerve stimulation (VNS) for epilepsy/depression and is currently developing DBS. Comparable to Nurotron in implantable neurostimulation category but as part of a diversified cardiac surgery + neuromodulation portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/nurotron

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nurotron Biotechnology